Safety and Efficacy Data: The CheckMate 9ER Trial

Robert Alter, MD, reviews the CheckMate 9ER trial of cabozantinib/nivolumab versus sunitinib in advanced renal cell cancer.

Related Videos
Experts on HCC
Experts on urothelial carcinoma
Experts on urothelial carcinoma
Experts on urothelial carcinoma
Experts on urothelia carcinoma
Experts on urothelial cancer
Experts on urothelial carcinoma
Experts on urothelial carcinoma
Experts on urothelial carcinoma
Related Content